Find clinical trials for Endometrial Cancer in Portland, OR
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Endometrial Cancer trials near Portland, OR, USA:
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...
Phase 1, Phase 2
Portland, Oregon, United States and 20 other locations
study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial...
Phase 2
Portland, Oregon, United States and 20 other locations
fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate ...
Phase 2
Portland, Oregon, United States and 10 other locations
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...
Phase 1
Portland, Oregon, United States and 20 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Tigard, Oregon, United States and 202 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
Portland, Oregon, United States and 82 other locations
in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-re ...
Phase 1
Portland, Oregon, United States and 17 other locations
in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSigna...
Phase 1, Phase 2
Portland, Oregon, United States and 66 other locations
will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors...
Phase 1, Phase 2
Vancouver, Washington, United States and 16 other locations
T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors...
Phase 1
Portland, Oregon, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal